MedTrace Logo

Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome

NCT04794569 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-04-04

No results posted yet for this study

Summary

The TILE pilot study will be a multicenter, open-label, assessor-blinded RCT (randomized control trial) comparing extended LMWH (Low Molecular Weight Heparin) vs. DOAC (Direct Oral Anticoagulants) to PTS (prevent post thrombotic syndrome) in patients with DVT (Deep Vein Thrombosis).

Conditions

  • Deep Vein Thrombosis
  • Post Thrombotic Syndrome

Interventions

DRUG

tinzaparin

low molecular weight heparin

DRUG

Rivaroxaban

direct oral anticoagulant

Sponsors & Collaborators

  • LEO Pharma

    collaborator INDUSTRY

  • Sunnybrook Research Institute

    collaborator OTHER

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Jean-Philippe Galanaud, MD · Sunnybrook Health Sciences Centre (Toronto, Ontario, Canada)

  • Susan R Kahn, MD · Jewish General Hospital (Montreal, Quebec, Canada)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-15
Primary Completion
2024-01-19
Completion
2024-01-19

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04794569 on ClinicalTrials.gov